Transcript
Lung cancer is the leading cause of cancer death worldwide.
Non small cell lung cancer, or NSCLC, represents 85% of all lung cancer and is associated with biomarkers that may provide information about a patient's cancer.
The NSCLC biomarker landscape is rapidly evolving with an increasing number of identified molecular biomarkers.
Detection of an actionable biomarker may guide a personalized treatment plan for patients with NSCLC.
About 45% of patients with non squamous NSCLC... have an actionable molecular biomarker, with EGFR and KRAS G12C as the two most common, representing one third of NSCLC patients.
